CD274 and esophageal squamous cell carcinoma: Another phase III KEYNOTE-181 study showed that pembrolizumab provided a median overall survival of 10.3 vs. 6.7 months with chemotherapy as second-line therapy in patients with ESCC and PD-L1 CPS of 10 or more (12).